General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-04-25 | 2024-03 | -1.49 | -1.32 | 0.17 | 11.41% |
2024-02-06 | 2023-12 | 1.76 | 1.72 | -0.04 | -2.27% |
2023-11-07 | 2023-09 | 1.91 | 2.29 | 0.38 | 19.90% |
2023-08-03 | 2023-06 | 1.6 | 1.34 | -0.26 | -16.25% |
2023-04-27 | 2023-03 | 1.63 | 1.37 | -0.26 | -15.95% |
2023-02-02 | 2022-12 | 1.5 | 1.67 | 0.17 | 11.33% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-07 | B of A Securities | Upgrade | Neutral | Buy |
2023-09-05 | Truist Securities | Upgrade | Buy | Buy |
2023-09-05 | HSBC | Upgrade | Reduce | |
2023-09-05 | Truist Securities | Upgrade | Buy | Buy |
2023-08-08 | Benchmark | Upgrade | Buy | Buy |
2023-08-03 | RBC Capital | Upgrade | Sector Perform | Sector Perform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-05-07 | BARTON JACQUELINE K | Director | 24.54K | Stock Award(Grant) |
2024-03-07 | DICKINSON ANDREW D | Chief Financial Officer | 134.98K | Conversion of Exercise of derivative security |
2024-05-07 | LOVE TED WENDELL | Director | 2.82K | Stock Award(Grant) |
2024-05-07 | MANWANI HARISH | Director | 12.87K | Stock Award(Grant) |
2024-03-07 | MERCIER JOHANNA | Officer | 118.43K | Conversion of Exercise of derivative security |
2024-03-07 | O'DAY DANIEL PATRICK | Chief Executive Officer | 484.85K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 126.19M | 9.73B | 10.13% |
2023-06-29 | Vanguard Group Inc | 113.37M | 8.74B | 9.10% |
2023-06-29 | Capital World Investors | 80.93M | 6.24B | 6.50% |
2023-06-29 | State Street Corporation | 59.32M | 4.57B | 4.76% |
2023-06-29 | Capital Research Global Investors | 57.90M | 4.46B | 4.65% |
2023-06-29 | Dodge & Cox Inc | 33.98M | 2.62B | 2.73% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 38.97M | 3.00B | 3.13% |
2023-09-29 | Income Fund of America Inc | 34.44M | 2.58B | 2.76% |
2023-06-29 | Vanguard 500 Index Fund | 29.70M | 2.29B | 2.38% |
2023-06-29 | Dodge & Cox Stock Fund | 24.24M | 1.87B | 1.95% |
2023-08-30 | Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF | 21.14M | 1.62B | 1.70% |
2023-09-29 | Washington Mutual Investors Fund | 20.14M | 1.51B | 1.62% |
Dividend | Date |
---|---|
0.77 | 2024-06-14 |
0.77 | 2024-03-14 |
0.75 | 2023-12-14 |
0.75 | 2023-09-15 |
0.75 | 2023-09-14 |
0.75 | 2023-06-14 |
Split | Date |
---|---|
2 : 1 | 2013-01-28 |
2 : 1 | 2007-06-25 |
2 : 1 | 2004-09-07 |
2 : 1 | 2002-03-08 |
2 : 1 | 2001-02-22 |
$GILD needs a new C suite. All of them. Whatever happened today there is no excuse. If top heavy with scientists get some business people in there FAST. Once in a lifetime opportunity for Gilead and the planet and they are fumbling it away. If you cannot stand the corona get out of the kitchen.
I agree to ignore anything from China/WHO a**holes trying to inflict even more propaganda and depression on America. The only trial results that matter are the two being conducted by Gilead outside China in multiple sites and coming soon. It wouldn’t surprise me if the Chinese have already been using the generic compounds on their people which may explain some of the lower infections.
Any more good news from anywhere $GILD will top $100, and when Remdesivir is approved for broad application to large patient populations it will double from here. In months ago, added today and glad.
$GILDGilead Pours Cold Water On Report That Sent Market Soaring: "Anecdotal Reports With No Statistical Power" | Zero Hedge https://www.zerohedge.com/health/gilead-pours-cold-water-report-sent-market-soaring-anecdotal-reports-no-statistical-power
Bought 10 Shares in 1 Position, with a 2 percent margin, for around $85.00 in total costs, plus commission ~$115.00
10 Shares at 77.180
89.000 equals to $165.77 in Gains
But my Strategy as a Hedge Fund Manager, I use the Compound Interest Strategy or the Magic Penny is Called...
At his wife’s urging, Michalak went to the University of Chicago Medicine hospital on Friday, April 3. His fever had spiked to 104 and he was struggling to breath. At the hospital, he was given supplemental oxygen. He also agreed to participate in Gilead’s severe Covid-19 clinical trial.
His first infusion of remdesivir was on Saturday, April 4. “My fever dropped almost immediately and I started to feel better,” he said.
By his second dose on Sunday, Michalak said he was being weaned off oxygen. He received two more daily infusions of remdesivir and recovered enough to be discharged from the hospital on Tuesday, April 7.
“Remdesivir was a miracle,” he said.
The world is waiting to find out if it is really so.
Very little if any of any of Chinese data or trials will be used to evaluate Remy. No matter how well intentioned their scientists may be, the narrative is controlled by Chinese Communist Party and China has desires to patent their own generic drug from the raw materials used in Remy. The real evaluation is 2400 pt ww Gilead study concluding in next few weeks using 4 subsets of pt involvement . Rely on that!